FIELD: medicine.
SUBSTANCE: invention relates to medicine and consists in application of serotonin 5-HT3 receptor antagonist for treatment of damages during vestibular disorders, wherein, mentioned damage is characterized by damage of internal ear cells and/or vestibular nerve cells, wherein, serotonin 5-HT3 receptor antagonist is selected from a group comprising ondansetron, palonosetron, tropisetron, lerisetron, alosetron, granisetron, dolasetron, bernesetron, ramosetron, azasetron, itasetron, zakoprid and cilansetron; and mentioned serotonin 5-HT3 receptor antagonist is introduced to the patient, at least during 5 days.
EFFECT: treatment of damages during vestibular disorders.
4 cl, 4 ex, 6 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPY OF TINNITUS INDUCED BY COCHLEAR EXCITOTOXICITY | 2005 |
|
RU2380094C2 |
| SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR TREATING VESTIBULAR DISORDERS | 2009 |
|
RU2589846C2 |
| LENTIVIRAL VECTORS PSEUDOTYPED BY MUTANT BaEV GLYCOPROTEINS | 2012 |
|
RU2618864C2 |
| IMMUNE CELLS DEFECTIVE BY Suv39h1 | 2018 |
|
RU2784531C2 |
| METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF KIDNEY CANCER | 2017 |
|
RU2752322C2 |
| ADENOVIRAL VECTOR CODING HOMOLOG-1 OF HUMAN ATONAL PROTEIN (HATH1) | 2015 |
|
RU2707131C2 |
| APPLICATION OF PHENOTHIAZINE DERIVATIVE TO PREVENT AND/OR TREAT HEARING LOSS | 2005 |
|
RU2377992C2 |
| MONOCLONAL ANTIBODIES AGAINST CLAUDIN 1 FOR PREVENTION AND TREATMENT OF HEPATOCELLULAR CARCINOMA | 2016 |
|
RU2770021C2 |
| AGENT SHOWING SEROTONIN 5-HT-RECEPTOR ANTAGONIST PROPERTIES | 2010 |
|
RU2438669C1 |
| FOOD RATION-CONTROLLED EXPRESSION OF NUCLEIC ACID ENCODING Cas9 NUCLEASE, AND ITS APPLICATIONS | 2017 |
|
RU2771383C2 |
